Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837438 | 0.87 | ALDH1A1 (0.39) | ALDH1A1MAPTL3MBTL1KDM4ELMNA | |
| SCHEMBL837253 | 0.87 | MPO (0.45) | SLC6A4ALDH1A1MAPTL3MBTL1KDM4E | |
| SCHEMBL837919 | 0.86 | MTNR1A (0.50) | HTR2AALDH1A1MAPTL3MBTL1KDM4E | |
| SCHEMBL838321 | 0.82 | PKM (0.55) | HTR2AALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL837267 | 0.81 | NR4A2 (0.39) | NR4A2HTR2AAHRSLC6A4ALDH1A1 | |
| SCHEMBL837466 | 0.81 | MAPK1 (0.35) | ALDH1A1MAPTL3MBTL1KDM4EHSD17B10 | |
| SCHEMBL23438306 | 0.79 | TSHR (0.47) | NR4A2HTR2AHSD17B10 | |
| SCHEMBL836527 | 0.78 | CDK2 (0.38) | ALDH1A1MAPTL3MBTL1KDM4ELMNA | |
| SCHEMBL836528 | 0.78 | NR4A2 (0.43) | NR4A2AHRALDH1A1MAPTL3MBTL1 | |
| SCHEMBL12585072 | 0.76 | GPR84 (0.46) | ALDH1A1MAPTKDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081214-A2 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2384753-B1 | Hydantoin derivatives as inhibitors of cellular necrosis | BRIGHAM & WOMENS HOSPITAL (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8741942-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130158024-A1 | TRICYCLIC NECROSTATIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-06-20 | — | — | US | disclosed |
| US-20130158024-A1 | TRICYCLIC NECROSTATIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-06-20 | — | — | US | disclosed |
| US-8324262-B2 | Tricyclic necrostatin compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143300-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2384753-A1 | Hydantoin derivatives as inhibitors of cellular necrosis | The Brigham and Women's Hospital, Inc. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110144169-A1 | Inhibitors of cellular necrosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| US-20100190836-A1 | Compounds, Screens, and Methods of Treatment | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-07-29 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2007075772-A2 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1663184-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005077344-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050119260-A1 | Inhibitors of cellular necrosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190836-A1 | Compounds, Screens, and Methods of Treatment | NLN, HTRA2, CLN6 | NR4A2 1846/4885HTR2A 2249/4885AHR 3911/4885 |
| US-20050119260-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | NR4A2 3992/4885HTR2A 4015/4885AHR 4812/4885 |
| US-20110144169-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | NR4A2 3992/4885HTR2A 4015/4885AHR 4812/4885 |
| US-20130158024-A1 | TRICYCLIC NECROSTATIN COMPOUNDS | HTRA2, AIFM1, BAD | NR4A2 2174/4885HTR2A 2035/4885AHR 4036/4885 |
| US-20120149702-A1 | INHIBITORS OF CELLULAR NECROSIS | TNF, AIFM1, BAD | NR4A2 3992/4885HTR2A 4015/4885AHR 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.